Skip to main content

Heart Valve Bioengineering

  • Reference work entry
  • First Online:
Organ Tissue Engineering

Abstract

Valve degeneration and dysfunction affect an increasing number of aging patients in the developed countries, while congenital and rheumatic diseases affect younger patients worldwide. When possible, valvular disease is treated by valve repair; however, severe pathologies require a surgical or transcatheter valve replacement procedure. Nowadays, clinical-grade valvular prostheses consist of mechanical or bioprosthetic valves, which still present serious disadvantages, such as thrombogenicity and limited durability.

In this chapter, we describe how tissue-engineered heart valves (TEHVs) can solve the shortcomings of current clinically adopted valvular replacements by providing a prosthesis with potential regenerative and remodeling capabilities and, hence, a lifelong durability. Different tissue engineering (TE) approaches, such as in vitro, in vivo, and in situ are described, with particular focus on preclinical and clinical validation of TEHVs. In this context, we will also discuss in silico, in vitro, and in vivo models that can be used to manufacture TEHVs, test their functionality, and predict their remodeling before moving to preclinical and clinical settings. Finally, we address the scientific, regulatory, and clinical challenges that pace the safe clinical translation of TEHVs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 449.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 499.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

Download references

Acknowledgments

S.P. Hoerstrup is a shareholder at Xeltis BV and LifeMatrix AG. M.Y. Emmert is a shareholder at LifeMatrix AG. The other authors have nothing to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Simon P. Hoerstrup .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Fioretta, E.S., Motta, S.E., Gähwiler, E.K.N., Poulis, N., Emmert, M.Y., Hoerstrup, S.P. (2021). Heart Valve Bioengineering. In: Eberli, D., Lee, S.J., Traweger, A. (eds) Organ Tissue Engineering. Reference Series in Biomedical Engineering(). Springer, Cham. https://doi.org/10.1007/978-3-030-44211-8_4

Download citation

Publish with us

Policies and ethics